ArticleJAMA ophthalmology2022

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US.

Mahyar Etminan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.